الفهرس Only 14 pages are availabe for public view
 |  | from | 192 |  |  |
| | | from | 192 | | |
Abstract
The main goal of this work is to employ the liquisolid technology to enhance the dissolution properties of a class Biopharmaceutics classification system (BCS) class II drug by adsorbing the drug in solution or self emulsifying form onto carrier and coating materials thus transforming it to a dry looking, free flowing and readily compressible powder. Thus by enhancing the dissolution properties of the drug, the bioavailability would significantly increase. Leflunomide was used in this study as an example of class BCS-II drugs. It is a novel drug with wide applications and thus is a perfect candidate for liquisolid application. It is a disease-modifying antirheumatic drug (DMARD) used in active moderate to severe rheumatoid arthritis and psoriatic arthritis. Leflunomide is available as oral tablets containing 10, 20 and 100mg. It is an official drug in BP 2013 and USP 36